Concepedia

Jiamei Yang

JY

Statistics

Publications

30

Citations

3.1K

H-Index

22

Active since

2000

Affiliations

Second Military Medical University(Current)

Eastern Hepatobiliary Surgery Hospital

First Affiliated Hospital of Xiamen University

Bayer (United States)

First Affiliated Hospital of Zhengzhou University

Jiamei Yang is an author at Second Military Medical University specializing in oncology, medicine, and liver cancer.

ORCID

Publications per year

2000–2023

30

Publications

30

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro et al. · The Lancet Oncology · 2015 · 1.1K citations

, , +17

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial

Riccardo Lencioni, Josep M. Llovet, Guohong Han et al. · Journal of Hepatology · 2016 · 692 citations · Full text

, , +5

Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial.

Riccardo Lencioni, Josep M. Llovet, Guohong Han et al. · Journal of Clinical Oncology · 2012 · 147 citations

, , +15

The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma

Zhijian Zhang, Qi Liu, Jia He et al. · Cancer · 2000 · 119 citations

, , +15

Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429

Chengjun Sui, Yanming Zhou, Weifeng Shen et al. · Journal of Molecular Medicine · 2016 · 100 citations

, , +14

1–5 of 30